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ABSTRACT
Nanoparticles have become very useful as delivery systems in biomedicine. The nanoparticles
can be layered with different compounds to produce a vessel for transport of biological materials.
Specifically, gold nanoparticles layered with a reducing agent, lysozyme, and polyelectrolytes
can be synthesized to transport lysozyme into a cell. However, zinc oxide nanoparticles are
cheaper, biocompatible nanoparticles that can be used for the same process. Here in, zinc oxide
nanoparticle conjugates were synthesized, modified, and analyzed to be used as a biological
material delivery system. The zinc oxide nanoparticles were synthesized using zinc chloride and
sodium hydroxide. The particles were then layered using the layer-by-layer technique of adding
each compound to the nanoparticle solution dropwise. Each deposition was bound by the
interaction of the opposite charges of the compounds being added. The layers used were
mercaptoundecanoic acid (MUA), poly(ethylenimine) (PEI), polystryrene sulfonate (PSS), and
RNA or lysozyme ordered specifically to have a high affinity for binding each layer. With each
deposition added to the system, the following instruments were used to characterize the particles:
Dynamic Light Scattering Spectroscopy (DLS) and Scanning Electrons Microscopy (SEM) for
particle sizing, Electrophoretic Mobility (ELS) for zeta potential and surface charge, and UV-Vis
spectrophotometer and FTIR spectroscopy for optical properties. Furthermore, after the layering
process was completed, the biological material encapsulated was tested to assure its effectiveness
once transported into the cell. This was completed using an enzymatic assay for lysozyme and an
ethidium bromide assay for RNA. After characterization was completed, all three nanoparticle
conjugates were concluded to be successfully synthesized.
KEYWORDS: zinc oxide, protein, protein delivery, lysozyme, RNA, nanoparticles,
nanomaterials, layer-by-layer.
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CHAPTER 1. INTRODUCTION

Section 1.1 Nanoparticles as a Delivery Platform
The nanoscale has been researched immensely for over the last century beginning with
Michael Faraday discovering that colloidal gold has a ruby red color.1 Elemental gold is well
known for the bright yellow, or gold, color that it has. However, on the nanoscale, it actually
appears red or purple. From that point on, nanoscale materials were slowly making an
appearance in the scientific field. Nanotechnology was first introduced by Richard P. Feynman
in his 1959 lecture called “There’s Plenty of Room at the Bottom”.2 He discussed the ground
breaking idea of manipulating individual atoms. However, his lecture went unnoticed by the
science world until the early 1980s. In 1985, Louis Brus made the discovery of colloidal
semiconductor nanocrystals, termed quantum dots.1 From there, in 1991, Sumino Lijima
documented the first observation of carbon nanotubes. As nanomaterials and various instruments
to analyze atoms and nanoscale materials continued to be investigated, nanotechnology
companies began to emerge in the 1990s, such as Nanophase Technologies, Helix Energy
Solutions Group, and Nano-Tex.1 The science industry was fully embracing the discoveries of
nanomaterials and nanotechnology, but the general public did not until the early 2000s when
consumer products began using nanotechnology in their industries.1 The entire world is now
involved in nanomaterials and their development for products, science, medicine, etc.
The word “nanomaterial” is defined as a material with particles or constituents with
dimensions measuring in the nanoscale, or something that is produced by nanotechnology.3
Nanomaterials come in different types, morphologies, and dimensions. There are nanorods,
nanoparticles, nanospheres, nanowires, quantum dots, etc. The main characteristic they all have
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in common is that they are on the nanoscale in some way, where 1 nanometer (nm) equals 10-9
meters. For example, a nanometer is approximately 100,000 times thinner than the diameter of a
single human hair.3 Of the types of nanomaterials, nanoparticles (NPs) in particular are a
material that have at least one dimension measuring less than 100 nm, usually have a spherical
shape, and have interesting optical and magnetic effects.2,4 They are a naturally occurring
material and can also be produced synthetically in a lab.3 When researchers started examining
nanoparticles more closely, it was quickly found that the size of the particles can affect the
physiochemical properties of the material such as solubility, fluorescence, and optical properties.
This change in properties due to their size gives nanoparticles many more functions than regular
macro-sized particles. Furthermore, there are many different classifications of nanoparticles
based on what chemicals they are made of: carbon-based, metal, ceramic, semiconductor,
polymeric, and lipid based.2
Besides the different properties of each type of nanoparticle, the thing that makes
nanomaterials an anomaly in today’s society is their surface area. Nano-sized materials have a
much larger surface area than larger materials such as a 1 cm cube with a similar mass.5 The
bigger the surface area of a particle, the greater amount of it can come in contact with other
materials around it. To prove this statement, think of a cube that is 1 cm on each side which has a
surface area of 6 cm2. If that cube was filled with a bunch of tiny cubes 1 mm on each side, those
would each have a surface area of 6 mm2, which would total 60 cm2 for the entire mass taken up
by the cubes. Continuing with this thought, if the original cube was filled with 1 nm sized cubes,
each with a surface area of 6 nm2, this would total 60,000,000 cm2.5 This amount is equal to
6,000 m2 which is larger than a football field. This amazing property of nanoparticles is what has
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started countless studies on them and makes them useful in so many fields. Furthermore, an
increase in surface area causes faster reactions and catalysis.
With all the unique properties nanomaterial have, there are a wide range of applications
for them. Nanomaterials are used in the production of nanopowders for ceramics and similar
materials, nanocomposites, and nanoelectrochemical systems. Nanotubes have been used for
hydrogen storage, DNA chips, gene and drug targeting, nanoelectronics, and nanodevices.6
Nanoparticles are used for delivery of chemotherapy drugs, to make photocatalysts, fuel cells,
and solar cells. Nanowires are used in flexible solar cells, to decompose organic molecules in
polluted water, and to make dense computer memory.7 Some of the most ground-breaking and
useful research done with nanomaterials have occurred in the biology and medical fields.
Specifically, applications such as fluorescent biological labels, drug and gene delivery, biodetection of pathogens, probing of DNA structure, tissue engineering, detection of proteins, MRI
contrast enhancement, and phagokinetic studies.4 The proceeding sections will discuss the idea
of drug delivery more thoroughly.
Through many research projects, it has been demonstrated that nanomaterials can also be
used to protect, stabilize, and preserve the activity of proteins in cells and in other materials.8,9
These ideas can be used in many different areas of science. In particular, protein stabilization and
delivery have important applications, such as manipulation of signaling pathways, stimulation of
potent antitumor immune cells, and tissue engineering 10,11 These applications can be
summarized as a delivery platform. Delivering proteins or drugs directly into cells can be
completed in a few different ways, although, due to the size of cells, it can be a difficult task.
Living organisms have cells that are generally 10 micrometers across so any form of delivery
mechanism must be smaller than that.4 Biological materials can be delivered into cells or other
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materials using a nanoparticle as the vessel. For example, Figure 1 shows a general scheme of
this delivery process of a protein transported into a cell. For this to occur, the protein (or other

Figure 1. Transporting a protein into a cell using a nanoparticle as the transport vessel.
material) must be bound in some way to the nanoparticle for transport. In addition, there must be
a transfection agent or mode of transfection for the vessel to move through the cell membrane
into the cell.12 Once transported into the cell, the protein will diffuse into the surrounding area by
some mechanism. There are many ways for the biological material to be bound to the
nanoparticle for the delivery process and many ways for it to be released into its surroundings.
Using a nanoparticle as a delivery method was first suggested in the 1970s. This idea was
put into the works in 1982 where a nanoparticles were devised as a carrier for vaccines and
anticancer drugs. To complete this, the research group looked at adsorbing, dissolving, or
encapsulating the biomaterial to attach it to the nanoparticle.54 Once the methods were working
for transport, in 1997, scientists began looking at how to control the release of the drug while
still protecting it from degradation. Once the 2000s came about, research groups were putting the
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idea of nanoparticle drug delivery into action. In 2004, Panyam, et al. encapsulated hydrophobic
drugs using biodegradable polymer nanoparticles.55
Another transport process that has been shown to work well in recent research was
encapsulation. This was completed by Wurster, et al. in 2013 and involves “encapsulating” the
biological material inside of the vessel before transporting. The encapsulation process can be
done through many different methods, one of which is the Layer-by-Layer technique used by
many research groups throughout the years which involves layering the nanoparticle vessel with
many layers.12 The general idea of the Layer-by-Layer method is to use a nanoparticle as the
core in a delivery system. Different layers of polymers or polyelectrolytes are then added on to
encapsulate a biological material such as a protein, enzyme, or nucleic acid inside the vessel.12
Electrostatic interactions would hold each layer together so that each one could be taken off
easily to release the biological material into the designated area. These interactions, also called
van der Walls interactions, are an attractive or repulsion between two or more objects having
electric charges.13 Each layer must therefore be oppositely charged to bind them together since
opposites attract. The weak interaction of the oppositely charged compounds is wanted so that
the enzyme can be exposed to its surroundings after a time. Having a weak interaction such as
the electrostatic interactions allows the release of the biomaterial to occur quickly and efficiently.
Figure 2 shows a possible layering scheme that could be completed to encapsulate DNA into the
vessel for delivery into a cell for gene editing.12 The core would need to be a non-toxic, metaltype nanoparticle, with a stabilizing agent such as mercaptoundecanoic acid (MUA) bound to it
to becoming the next layer in the encapsulation. This would cause the vessel to have a negative
surface charge that would then readily bind to a positively charged polyelectrolyte such as
poly(ethyleneimine) (PEI).12 After the layer of PEI, the DNA can readily bind due to nucleic
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Figure 2. Order of layers for the encapsulation of DNA.
acids have strongly negative charges from their phosphate backbones. The DNA would then be
the biological material being encapsulated inside the vessel for transport into the cell for
biological applications. Lastly, another layer of PEI would be layered on the outside of the vessel
to enclose the DNA inside and stopping it from being released too early. The positive charge of
PEI would strongly bind to the negative charge of DNA holding the vessel together. PEI would
be a good choice for the final layer due to it being a well-known transfection agent, meaning that
it can readily pass through a cell membrane for transportation.14
With this general layering idea, nanoparticles are shown to be a good mechanism to
transport biological materials into cells. Many research groups have completed this type of
research making the nanoparticle system into a delivery system. It has proved to be useful, but
still has a way to go. The purpose of this delivery system is for biological applications which
depend on what specifically is being transported. On a genetic level, diseases such as cancer,
Parkinson’s disease, Alzheimer’s disease, and rheumatoid arthritis are being looked at to
determine pharmaceutical interventions that could potentially cure them.15 Small molecules and
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proteins are two possible solutions. Small molecule drugs can be transported into cells to
deactivate or inhibit target proteins through competitive binding, whereas protein-based drugs
can bind to a variety of targets with high specificity and can be used as substitutes for mutated or
missing proteins.15 These drugs however cannot target every disease-relevant protein or gene,
and therefore are not always the best path to take in researching possible cures. Nucleic acids
such as mRNA and DNA are another possible solution through gene editing and regulation. This
is possible through specifically targeting Watson-Crick base pairing using gene editing.15 Gene
editing can permanently change the host’s DNA which is a possible way to cure the genetic
defect causing the underlying disease in question. With that in mind, nucleic acid delivery via
nanoparticles is an important avenue to be explored.

Section 1.2 Past Research with Gold Nanoparticles
Among the research completed on nanoparticles for drug transport, gold has been
investigated intensely, specifically with the Layer-by-Layer method described in brief earlier.
Gold nanoparticles have many unique properties such as size- and shape-dependent optical and
electronic features, an easily modifiable surface, biocompatibility and non-toxicity.16 These
properties make it good for use in a living system. Gold nanoparticles also have a high affinity to
interact with cells as well as to enter them.17 This property, along with others, makes gold a good
material for transport. The use of gold nanoparticles as a delivery method has been widely
researched in the past by many groups. One in particular looked at their ability to stabilize and
deliver material such as DNA, RNA, and proteins.17 To set up the gold nanoparticles for
delivery, they are normally stabilized by long hydrocarbon ligands to avoid aggregation. For
example, mercaptocarboxylic acid can be used due to the sulfur functional group being adsorbed
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by the gold surface while the carboxylic acid side points out towards the solution.17 This works
due to sulfur having a strong attraction to gold which binds the two materials together to form a
nanoparticle conjugate for further layering.
From there, the gold nanoparticle conjugate with mercaptocarboxylic acid bound to it can
be modified by binding biological molecules for delivery to it using many different methods
based on the material in question: thiol-gold affinity interactions, electrostatic interactions,
covalent linkage of amino groups, and physical adsorption.17 The specific method to be looked at
here uses electrostatic interactions and is called the Layer-by-Layer technique.12 It is described as
taking a nanoparticle core, encasing it with a ligand, binding the protein to that ligand, and
encapsulating the final product in oppositely charged polyelectrolytes. This process produces the
vessel in which the protein or material can be transported into cells for its release. Each layer is
bound by electrostatic interactions from the alternative charges of each layer to make the final
product one bound unit.12,17 This bound unit is then the nanoparticle conjugate for the transport
of biological materials.
Among the past research completed, I, along with other colleagues at Missouri State
University and the University of Valladolid in Spain, published a manuscript about using gold
nanoparticles as a delivery system for proteins titled In Situ Synthesis, Stabilization and Activity
of Protein-Modified Gold Nanoparticles for Biological Applications.16. The research going along
with the manuscript was completed in our lab at Missouri State University. Specifically, we
synthesized the delivery vessel of gold nanoparticles (AuNPs) and encapsulated lysozyme (Lys)
using the Layer-by-Layer technique discussed earlier. The goal of this was to demonstrate the
stability and activity of lysozyme within the nanoparticle conjugate for later adaptation for use
with other proteins or biomaterials.16 The layers used for this specific nanoparticle conjugate
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were mercaptoundecanoic acid (MUA), polystyrenesulfonate (PSS), and polyethyleneimine
(PEI) to create the oppositely charged layers for encapsulation. The order of layering was as
follows: AuNPs-MUA-PEI-PSS-Lys-PSS-PEI and AuNPs-Lys-PSS-PEI.16 Figure 3 is a general
scheme of these experiments to produce two different AuNPs vessels for lysozyme transport.
The gold nanoparticles were synthesized with HAuCl4 and a reducing agent (lysozyme or
sodium citrate) prior to the layering process.16 The entire procedure was completed without any
activators and at near ambient conditions. To layer the particles, the Layer-by-Layer procedure
discussed earlier was modified slightly to work for lysozyme as the biological material in place
of DNA.12 The order of layers had to be adjusted slightly due to the charge of lysozyme being
positive to keep the electrostatic interactions working to bind each layer to the vessel.

Figure 3. Methods for synthesizing gold nanoparticle conjugates showing the synthesis of
Lys-AuNPs (Aa), PEI-PSS-Lys-AuNPs (Ab), citrate-AuNPs (Ba), MUA-AuNPs (Bb) and
PEI-PSS-Lys-PSS-PEI-MUA-AuNPs (Bc) (Not to scale).16
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After the synthesis process, characterization was completed using many techniques such
as UV-Vis spectrophotometry, dynamic light scattering, electrophoretic mobility light scattering,
transmission electron microscopy, Fourier-transform infrared spectrometry, as well as a
lysozyme activity assay. The results from dynamic light scattering showed that after each
deposition, the particles diameter increased, ending at ~130 nm.16 The zeta potential and optical
properties using UV-Vis spectrophotometry were also measured and showed successful
depositions after each step in the process. FTIR spectroscopy was used to assure the presence of
lysozyme midway through the deposition process. With all the results obtained, it was
determined that the vessel was successfully synthesized with lysozyme encapsulated inside.
However, the lysozyme must be checked for its activity to make sure it was still able to be used
to degrade bacteria. This was completed using Micrococcus lysodeikticus bacteria to observe the
enzymatic action of lysozyme.16 Figure 4 shows the enzymatic activity of lysozyme obtained
from this research for free lysozyme and the encapsulated lysozyme nanoconjugates. It was seen
that the free lysozyme reacted as predicted when added to a sample of bacteria with its activity
greatly decreased from the start of the reaction reaching nearly zero activity within 12 minutes.16
The layered bioconjugate samples, however, had different behaviors. These samples had an
increase in activity while the outside layers were being removed from the vessel. Once the
lysozyme was released into the solution of bacteria after 6 minutes for the PEI-PSS-Lys-PSSPEI-MUA-AuNP sample, the activity began to decrease to zero in 24 minutes. On the other
hand, for the PEI-PSS-Lys-AuNP sample, the activity continued increasing after 6 minutes
reaching a plateau.16 This shows the interaction between lysozyme and the nanoparticles actually
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Figure 4. Enzymatic activities of free lysozyme and the lysozyme-gold nanoparticle
bioconjugates expressed as EU/mLenzyme sample.16
prolongs the activity of the lysozyme in the sample. Furthermore, these results support that the
layered samples would be able to be transported into a cell before releasing the lysozyme. It also
shows that the lysozyme is still able to degrade bacteria even after being encapsulated inside the
vessel.16
The model protein encapsulated within the polyelectrolytes in two of the delivery systems
discussed was lysozyme, 1,4-β-N-acetylmuramidase.35 Specifically, lysozyme is a small globular
protein with a molecular weight of 14.6 kDa. It consists of 129 amino acid residues containing
four disulfide bonds with a relatively rigid structure according to X-ray crystallography.29 At
physiological conditions, lysozyme is folded into a tight globular structure with a cleft on the
surface of it which is its active site.35 Figure 5 shows the tertiary structure of lysozyme. This
enzyme is also in very high abundance in our world making it inexpensive and easily obtainable.
More specifically, lysozyme is found in plants and animals, specifically in milk, tears, saliva, egg

11

Figure 5. The tertiary structure of lysozyme with the active site shown.35
whites, and cervical mucus.35 The importance of lysozyme lies in its natural antibacterial and
antiviral abilities. Its function is to degrade bacteria by breaking the chemical bonds in the
bacterial cell wall.35
With this project, lysozyme is a good model protein for exploring its interaction with
nanoparticles and delivery systems. Furthermore, lysozyme can actually be stabilized by
intermolecular electrostatic interactions.36 For the encapsulation process in this research,
lysozyme was bound to the delivery system in two different ways, similar to the past research
completed with gold nanoparticles.16 One method bound the lysozyme directly to the
nanoparticle through reduction, where the other method used the stabilizing agent, MUA,
between the two. The MUA binds to the lysozyme by electrostatic interactions since MUA has a
negative charge from the deprotonated sulfur atom, and lysozyme has an overall positive charge
due to more positive amino acids than negative ones.12,29 Lysozyme also has many properties
that make it ideal as a model. It is a well characterized protein with a high isoelectric point of
11.35.35 In addition, lysozyme is stable over wide temperature and pH ranges, making it suitable
for a variety of synthetic approaches. These properties also make lysozyme an attractive model
protein for various applications. Therefore, a wide number of attempts to investigate different
12

ways to immobilize or encapsulate lysozyme, many of which include Layer-by-Layer steps
during the process, have emerged.38,39,40
Through this research, specific polyelectrolytes were added to the nanoparticle
conjugates. Polystyrene sulfonate (PSS) and polyethyleneimine (PEI) were added after the MUA
and lysozyme in this case to finish the encapsulation process for later transport. PSS is a salt with
a negative charge at physiological pH. PEI is a well-known transfection agent that is positive at
physiological pH. These layers are attached to the conjugate by electrostatic interactions from the
opposing charges between the compounds.12 Figure 6 shows the branched structures of PSS (left)
and PEI (right) in their general forms. At physiological pH, however, PSS has a negative charge
on the oxygen atoms, and PEI will be protonated on the –NH2 groups to be –NH3+ groups
making the compound have an overall positive charge.12 These charges account for how the
electrostatic interactions between each layer work to bind the nanoparticle conjugate together.

Figure 6. Polyelectrolyte branched structures of (left) PSS and (right) PEI at physiological pH.

While going through the layering process with the electrostatic interact ions, there was a
possibility that the nanoparticle conjugates would aggregate or be measured as a large size than
expected. This could be fixed by sonication or vortexing, but sometimes there is another
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phenomenon occurring that cannot be helped. Ostwald Ripening is when smaller particles within
a solution attach themselves to a larger particle in order to become more stable.51 This occurs
because some molecules are more thermodynamically stable than others causing the unstable
surface molecules to bind to larger particles in an attempt to stabilize themselves. This can also
cause the particles to shrink over time due to the unstable molecules going into solution
instead.51 Basically, smaller particles will continue to decrease in size as parts of it go into
solution due to be unstable, while larger particles continue to grow from other parts of the small
molecules adding on to them. Overall, this can cause the observed diameter of the nanoparticle
conjugates to be an unexpected value that is difficult to explain. Figure 7 (B) show an example of
how this phenomenon occurs with smaller particles adding to larger particles to make one overall
larger nanoparticle conjugate.

Figure 7. Examples of (A) Coalescence and (B) Ostwald Ripening to account for particle
aggregating within a solution.52
Another possible cause of aggregation within the nanoparticle conjugate solution is called
coalescence. Coalescence refers to overall particle growth through many stages of particle
aggregation followed by grain growth.53 This occurs due to the nanoparticles trying to reduce
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their overall surface energy. Many research groups have monitored this event with gold
nanoparticles in particular. Specifically, it has been observed that the nanoparticles start out by
forming a neck with a group of particles, and then turn into a quasi-spherical shape through
relaxation.53 The group of particles forming the sphere then will be measured with a larger
overall diameter since they are grouped together so tightly. Figure 7 (A) shows an example of
how these particles group together to form an overall large diameter nanoparticle.
Overall, this research demonstrated the synthesis and stabilization of layered gold
nanoparticles at near ambient conditions.16 Lysozyme was successfully encapsulated into the
vessel for later transport into cells via transfection. This research project was done specifically
for lysozyme, looking at its stabilization and activity throughout the experiment. Lysozyme was
used as a model in this protocol and could readily be modified for the transport of other proteins
or biological materials.16 This research also demonstrated that nanoparticles, gold in this specific
case, can be used as the core in the encapsulation process of a biological material for transport
into cells. More specifically, nanoparticles can be used as a delivery system for drugs as well as
other materials. With this project being used as a guide, much more can be done in this field with
nanomaterials and delivery systems. Both the nanoparticle core and the biological material
encapsulated can ideally be interchanged with other compounds and materials for further
investigation of this process.
One such biomaterial that can be swapped for lysozyme is ribonucleic acid. Ribonucleic
acid (RNA) is one of the major biological macromolecules found in all known life forms.41 It is
similar in structure to deoxynucleic acid, DNA, but has one more –OH group attached to the
ribose ring. Furthermore, RNA is single-stranded unlike DNA. Figure 8 shows a simple
backbone structure of a strand of RNA. It has a backbone with alternating ribose, which is sugar,
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Figure 8. General Structure of Ribonucleic Acid.

and phosphate groups. Then, attached to each ribose is one of the four possible bases: cytosine
(C), guanine (G), adenine (A), or uracil (U).42 The negative charge on the phosphate groups
accounts for the overall negative charge on the structure. There are also different types of RNA
within each cell. Specifically, there is messenger RNA, ribosomal RNA, and transfer RNA to list
a few. Small RNAs have been found to be useful in gene expression and gene editing over the
past several years.42 Specifically, the RNA sequence could silence gene replication by binding to
the end of another sequence. With that in mind, encapsulating RNA in the nanoparticle conjugate
can therefore be used for gene regulation once transported into the cell.
Once encapsulated inside the nanoparticle conjugate, the RNA must still be intact to be
useful for gene regulation. If the RNA degrades, it will break into nucleotides becoming
ineffective for targeting genetic mutations.43 Just like with lysozyme, once the encapsulation
process is completed with RNA successfully in the nanoparticle conjugate, its integrity must be
tested to assure that it is still intact and able to be used for gene regulation in the future. To do
this, an ethidium bromide assay can be used with measuring fluorescence to determine if the
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RNA is degraded or not.44 Ethidium bromide is an intercalating agent, meaning it inserts itself
between the planar compounds in other molecules. It is commonly used as a fluorescent tag with
DNA or RNA, which is its purpose here. Ethidium bromide binds readily to intact RNA and
becomes very fluorescent. If the RNA is degraded, however, the fluorescence of the RNA will
greatly decrease the fluorescence of the bound ethidium bromide due to it being fragmented.45
This causes the binding affinity of ethidium bromide to the sequence to greatly decrease. That
being said, the fluorescence is a good determining factor to show whether the RNA is intact.
To compare the encapsulated RNA to intact RNA and degraded RNA, a sample of RNA
must be degraded before having its fluorescence with ethidium bromide tested. There are many
laboratory methods for degrading RNA such as adding a strong base, reducing the pH to below 4
with an acid, or heating it above 120oC for a certain amount of time.43 Each of these methods
causes RNA to be unstable and degrade over time. Degraded RNA will not be useful as a drug.
For the ethidium bromide assay, two of these methods were used to degrade a sample of intact
RNA to determine its fluorescence when bound to RNA.44

Section 1.3 Zinc Oxide Nanoparticles
Although the research with gold was promising, the chemicals needed to synthesize gold
nanoparticles are expensive. Looking at alternative nanomaterials, zinc oxide (ZnO) is a common
inorganic, semiconducting compound with a wide band gap of 3.37 eV that has been found to
form nanostructures under certain conditions.21 It is insoluble in water and has an extremely high
melting point of 1975oC. In nature, it occurs in the mineral zincite, but is usually synthesized for
industrial uses.22 The compound has three different crystalline forms that it exists in: salt,
wurtzite, and zincblende. These are shown in Figure 9. Of synthesized zinc oxide, the wurtzite
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Figure 9. Common Zinc Oxide Crystal Structures of (a) cubic rock salt, (b) cubic zincblende,
and (c) hexagonal wurtzite where grey and black spheres represent zinc and oxygen atoms
respectively.22
structure is observed more often due to it being more stable under ambient conditions.22
Recently, zinc oxide has emerged into the nanotechnology field for various applications. Before
then, it was well-known for its uses in electronics, optics, photonics, and rubber industries.22,23 In
the 1960s, films of zinc oxide were being synthesized to be used in sensors, transducers, and
catalysts. When nanotechnology started breaking scientific barriers, the zinc oxide films were
looked at more closely and could be synthesized as nanowires which could be used to make the
thin films in question.24 Reducing the compound to nano-size brought about many new surface
and optical properties that widened its uses in products.23
In regard to its use as a delivery system, zinc oxide has a few special abilities, such as
anticancer and antimicrobial activities, which make it a useful drug carrier.25 Zinc oxide has
actually been used in many health care products due to its efficient antimicrobial activity against
gram-positive and gram-negative bacteria. Research has been done to show the possible
mechanisms of this phenomenon such as the formation of reactive oxygen species or the release
of Zn2+ ions. Both cause damage to the bacteria cell membrane through various interactions.26
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Zinc oxide nanoparticles are also more affordable to synthesize than gold nanoparticles, as well
as many other nanoparticles, needing only two common compounds.26
Zinc oxide nanoparticles been shown to be potentially useful in nano-medicine and
biomedical sciences at select doses, although the toxicity is still being looked at by many
research groups28. Specifically, one study showed that injecting enough zinc oxide into
mammalian cells to cause bactericide did not have any cytotoxic effects on the mammalian
cells.26 Another important characteristic of zinc oxide is its ability to interact with enzymes,
especially lysozyme.27 It has been shown in past research that zinc oxide is capable of disrupting
protein-protein associations by binding to the protein in question.29 The zinc oxide nanoparticle
can bind to the largest cleft on the lysozyme surface, while retaining the secondary structure of
the enzyme. This also causes the protein to maintain its enzymatic activity, even under
denaturation.29
Through many research projects in the past decades, zinc oxide has been found to be a
versatile functioning material due to it having a wide range of growth morphologies besides the
general nanowires and nanoparticles: nanocombs, nanorings, nanohelixes, nanobelts, and
nanocages.23 Each morphology of the zinc oxide nanostructures has different physical and
chemical properties specific to it.21 This also helped widen the possible uses of zinc oxide
nanomaterials. Some important applications of zinc oxide that have emerged through of the years
are UV-light emitters, surface acoustic wave devices, ceramic varistors, transparent high-power
electronics, piezoelectric transducers, and catalysis via gas sensing.30
Today, there are many different methods in the literature for synthesizing zinc oxide
nanostructures. Some, but not all, are laser ablation, thermal decomposition, co-precipitation,
hydrothermal methods, ultrasound, electrochemical depositions, anodization, combustion
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method, sol-gel method, and chemical vapor deposition.21 Some synthetic processes can be
controlled to produce different morphologies such as solution concentration, pH, washing
medium, and chemical compounds used.21
Examining the precipitation methods, zinc oxide can be synthesized using multiple
combinations of compounds. Combining sodium hydroxide with either zinc chloride, zinc
acetate, or zinc nitrate will precipitate zinc oxide.27,31 The following reaction in Figure 10 shows
how zinc oxide is precipitated using zinc chloride as the zinc source.32 Some literature states that

Figure 10. Reaction for the synthesis of zinc oxide nanoparticles.

this reaction occurs in multiple steps with zinc hydroxide, ZnOH2, being an intermediate, and
then the hydrogens being removed when drying the solid sample to form the final product of zinc
oxide, ZnO. The trick to making the particles nano-sized is the conditions in which they are
synthesized. The solutions must be added together dropwise to have a very slow, regulated
reaction to form the zinc oxide precipitate. Ideally, the longer the reaction, the smaller the
particles will be.31 The solution must also be stirred strongly for the entire time of the addition of
the compounds. The other factors affecting the size of the particles are the temperature at which
they are synthesized, and how long the reaction takes place. Heating the particles at 90o C will
give a spherical shape, causing them to be smaller, while heating at 45oC will cause nanorods to
form instead.27 When combining these reactants, it is possible to form zinc hydroxide instead of
zinc oxide. UV-Vis spectroscopy can be used to assure that the proper compound was
synthesized. Zinc oxide is known to absorb at ~360 nm which is a quick, efficient way to test for
the product.32
20

The past research with gold can be adapted to use zinc oxide instead. The binding method
must be investigated to assure the layering will occur. One of the layers used in past research was
mercaptoundecanoic acid (MUA) which is a stabilizing agent and gives the nanoparticle
conjugate a negative surface charge that will readily bind to lysozyme.16 This is due to the MUA
having a negative charge on the sulfur atom after deprotonation at physiological pH. Gold has
been shown to readily bind to the sulfur in MUA due to gold having a high affinity for sulfur.
The sulfur will readily bind to the gold interface forming gold thiolate bonds. It is hypothesized
that zinc interacts the same way, even with the oxide on it. Figure 11 gives a general scheme of
how these bonds are hypothesized to occur. The Zn2+ will have a surface interaction with the
sulfur atom on the MUA to bind the nanoparticle to that ligand.34 Another hypothesized method

Figure 11. Binding Mechanisms of gold (left) and zinc (right) to MUA.33

of the binding of zinc oxide to sulfur is that the wurtzite crystal structure of zinc oxide has
oxygen vacancies. The sulfur atoms can then fill these vacancies and bind to the zinc in oxygen’s
place.
Furthermore, when binding the nanoparticle directly to the biological material lysozyme
in past research, the gold nanoparticles were synthesized with lysozyme as the reducing agent. If
zinc oxide is used instead of gold, the binding mechanism changes. When looking at the surface
charges of lysozyme and zinc oxide, they are both positive. With that in mind, it seems that these
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will not bind through electrostatic interactions as the rest of the layers do. However, that is
actually incorrect. Lysozyme has two catalytic residues in its binding site, Glu35 and Asp52.29
These amino acids are negatively charged at physiological pH which causes the binding site to
be negatively charged. With zinc oxide having a positive surface charge and the binding site on
lysozyme having a negative charge, electrostatic interactions do account for the binding
mechanism between the two materials.29

Section 1.4 Motivations
The past research with gold nanoparticles used as a vessel for transporting biological
material into a cell was a good starting point for delivery systems. Further research can be
completed to optimize the results and the system overall. The motivations of this research are to
develop a new nanoparticle conjugate system for drug delivery and show proof of concept by
changing the encapsulated material. Zinc oxide nanoparticles are more affordable to synthesize
and purchase than gold nanoparticles. This will allow the synthesis process to be more cost
effective. The procedures used by two different groups for layering, Wurster and et al. and
Garcia and et al., were modified for this project with zinc oxide to encapsulate lysozyme and
RNA in the nanoparticle conjugates for future transport into cells.12,16 Lysozyme was
encapsulated first to assure that the process would work with a model protein before moving on
to less stable biological materials such as RNA.
Overall, the synthesized nanoparticle conjugates would be another method for drug
delivery. This is a more specific way to deliver medicine to a certain area in the body.
Furthermore, gene regulation would be an end goal to potential fix gene mutations, cure diseases,
or produce proteins.
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Section 1.5 Objectives
The main goals of this research project:
1. To synthesize and characterize zinc oxide nanoparticle bioconjugates
2. To verify the biological activity of the zinc oxide nanoparticle bioconjugates
Three nanoparticle bioconjugates were synthesized and characterized: ZnO-Lys-PSS-PEI,
ZnO-MUA-Lys-PSS-PEI, and ZnO-MUA-PEI-RNA-PEI. With all this completed, the different
orders of the layering process were compared between all three systems. Furthermore, these
bioconjugates could potentially be used to transport the encapsulated material into mammalian
cells to destroy unwanted bacteria or edit mutated genes causing diseases.

23

CHAPTER 2. EXPERIMENTAL

Section 2.1 Materials
All chemicals and solvents were reagent grade and used without further purification.
Poly(ethyleneimine) (branched, 25 kDa), poly(sodium 4-styrenesulfonate) (branched, 70 kDa
and 1000 kDa), 11-mercapto-undecanoic acid, (MUA), Lysozyme (Lys) from chicken egg white,
bacteria Micrococcus lysodeikticus, Corning® syringe filters membrane (with diameter 15 mm
and pore size 0.2 μm), and RNA from torula yeast, type VI, were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Poly(ethyleneimine) (branched, 60 kDa) was purchased from Acros
Organics. Zinc chloride anhydride was bas purchased from Alfa Aesar. Sodium hydroxide and
sodium chloride was purchased from Fisher Scientific. Sodium citrate dihydrate and sodium
phosphate monobasic were purchased from Spectrum Chemical Manufacturing Group (Gardena,
CA, USA). Sodium phosphate dibasic was from purchased from Mallinckrodt Chemical Works
(St. Louis, MO, USA). The ethidium bromide was borrowed from Dr. Udan’s laboratory in the
Missouri State University Biology Department. Deionized water with a resistivity of 18.2
MΩ·cm-1 was used to prepare all the solutions.

Section 2.2 Methods
Many instruments and techniques were used in the synthesis and characterization of the
zinc oxide nanoparticle conjugates. Purification of zinc oxide nanoparticle suspensions was
performed using a micro-centrifuge (D3024 from Scilogex, Rocky Hill, CT, USA). Once
purified, multiple instruments were used to characterize each sample. X-ray diffraction (XRD)
was used to determine the crystal structure of the zinc oxide nanoparticles. Dynamic Light
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Scattering (DLS) and Electrophoretic Mobility Light Scattering (ELS) were used to measure the
diameter, polydispersity, and zeta potential of the particles before and after deposition
(NanoBrook Omni from Brookhaven Instruments, Holtsville, NY, USA). For particle sizing
measurements using the DLS, the samples were re-suspended in 1 mM NaCl and filtered with a
0.2 µm corning filters. Purified samples did not need to be filtered for zeta-potential purposes but
were re-suspended in 1 mM NaCl. An UV-Vis spectrophotometer was used for optical properties
and for the enzymatic activity assays (Cary-60, Agilent Technologies, Santa Clara, CA, USA).
Absorbance spectra were recorded from 200 to 800 nm. Size measurements and images were
obtained using a Scanning Electron Microscope (SEM) (Quanta 200 FEG, Oxford Instruments).
FTIR spectroscopy was used to obtain the transmittance spectra for the samples (Vertex 70,
Bruker). Finally, fluorescence spectroscopy was used for the ethidium bromide assay with the
RNA samples to test the nanoparticle conjugates integrity (Horiba Scientific, QM-8075-21-C).
Purification was completed as stated above before each analysis to assure the sample was not
contaminated. Sonication and/or vortexing was also completed after each purification step to
assure the particles were well dispersed and not aggregated within the sample.
Section 2.2.1 Dynamic light scattering spectroscopy. Dynamic Light Scattering (DLS)
is a characterization technique used by many research groups to analyze particle size.12 For this
research, it is an analysis method to determine if each layer was added to the bioconjugate. This
instrument measures the dynamic diameter and polydispersity of the particles in a conductive
solution. Polydispersity is the measure of non-uniformity of the particles, so a lower
polydispersity value is better. To find the diameter of the particles, a laser is passed through the
sample which scatters off the particles at different angles and intensities.18 The equation to
calculate the diameter is called the Stokes-Einstein Equation and is as follows: 𝐷ℎ =
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𝑘𝐵 𝑇
3𝜋𝜂𝐷𝑡

where Dh is the hydrodynamic diameter, Dt is translational diffusion coefficient, kB is
Boltzmann’s constant, T is temperature, and η is the dynamic viscosity.18 Using that equation,
the diameter of the particles can be determined which allows for further analysis to see if the
particles in question are nano-sized, and if each deposition is successful. A general scheme of
how the DLS instrument works is shown in Figure 12. This instrument works very well as long
as the particles are not aggregated, or clustered, within the sample. Aggregation of nanoparticles
can be avoided by making sure the particles are at a particular temperature, pH, or lighting, as
well as being in the proper solvent. If the particles do aggregate, it can be helped with sonication
or vortexing.

Figure 12. General Scheme of Dynamic Light Scattering Instrument.

Section 2.2.2 Electrophoretic mobility light scattering spectroscopy. Another major
technique used in the previous research was Electrophoretic Mobility Light Scattering (ELS) to
determine the zeta potential of the particles after each deposition.12 This analysis helps to
determine if each layer was bound successfully to the nanoparticle conjugate due to the charges
alternating which each deposition through the layering process. Zeta potential is the potential
difference between the surface of the particle and the conducting liquid it is immersed in.19 This
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can be determined through light scattering and creating a potential within the sample. An
electrode is placed in the sample to create the potential difference which will move the charged
particles to their respective sides—opposites attract. The light scattering is completed to
determine the electrophoretic mobility of the charged particles.19 It is then used to calculate the
zeta potential through the following two equations summarized as the Smoluckowski Equations:
µ=

𝜈
𝑉𝐿

and 𝜁 =

𝜂𝜇
𝜀

where µ is the electrophoretic mobility, ε is dielectric constant, ζ is zeta

potential, η is dynamic viscosity, ν is the speed of the particle, V is the voltage, and L is length of
the electrode.19 The general scheme of how the ELS works is shown in Figure 13.

Figure 13. General Scheme of Electrophoretic Mobility Light Scattering Instrument.

While doing experiments with this instrument, it was found that there is no universally
accepted standard for ELS measurements.20 While looking into what may work as a standard, an
inexpensive option that would work for the negative and positive ranges was found: Coffee Mate
coffee creamer. At an acidic pH at or below 3.0, this coffee creamer has a positive zeta potential,
and at a basic pH above 7.0, it has a negative zeta potential.20 Between those pH values, it gives
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a neutral zeta potential reading around 0.0 mV. With these findings, Coffee Mate could be used
as the standard for the later experiments taking place.
When investigating this possible standard, to assure that the expected values were
obtained, multiple trials for the positive and negative standards were completed and are shown in
Figure 14. To begin, a phosphate buffer containing KCl at pH 8.0 was made for the negative
standard, and a citric acid buffer at pH 3.0 was made for the positive standard. Then, about 5 mg
of Coffee Mate coffee creamer was dissolved in 10 mL of the respective buffer. Each sample
was sonicated thoroughly to assure the sample was fully dispersed and then brought to the ELS
for measuring. For each trial, a fresh sample must be made. If left for multiple days, the Coffee
Mate coffee creamer standard becomes contaminated and no longer charged. After testing
thirteen fresh samples for each standard, the positive standard was averaged at 32.88 mV ± 2.90
and the negative standard at -39.90 mV ± 3.84. The graphs shows each trial for both standards
measured with the ELS. With these standards, each use with the ELS can be assumed to be
correct as long as the proper values are being measured for these standards. Furthermore, these

Positive Coffeemate Standard
50

-10

40

Zeta Potentail (mV)

Zeta Potentail (mV)

Negative Coffeemate Standard
0

-20
-30
-40
-50

30
20
10
0

-60
0

1

2

3

4

5

6

7

8

0

9 10 11 12 13

Trial

1

2

3

4

5

6

7

Trial

8

9 10 11 12 13

Figure 14. Coffee Mate Standards for ELS with negative values on the left and positive values
on the right.
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results show that zeta potential of a substance can be dependent on pH in certain cases. This must
be considered when comparing literature values with experimental ones in future analyses.

Section 2.3 Synthesis of PEI-PSS-Lys-MUA-ZnO NPs
Zinc oxide nanoparticles were synthesized in the presents of mercaptoundecanoic acid to
obtain the core and first layer of the desired vessel as shown in Figure 15 (Method 2). This
synthesis was completed using a modified version of a well-known method called Layer-byLayer.12 To begin, 20 mL of 0.05% ZnCl2 was heated at a constant 45oC while stirring at 300
rpm. Then, 0.02 g of MUA was dissolved in 10 mL of 0.02 M NaOH by heating and stirring.
This solution was then added dropwise to the stirred solution of ZnCl2. It was left to react with
heating and stirring for various amounts of time ranging from 1 to 24 hours to vary the size of
the particles. The reaction was cooled to room temperature. The sample was washed and purified
using a centrifuge at 5000 rpm for 5 minutes. The sample was washed with deionized water once
and then resuspended in 1 mM NaCl.
Two different orders of layering can be completed with the MUA-ZnO NPs to form LysPSS-PEI-MUA-ZnO NPs and Lys-MUA-ZnO NPs. The one used here was Lys-MUA-ZnO NPs
to reduce the overall number of layers being added to the vessel. The other method would ideally
be just as useful, but more time consuming. For the layering process, a 10 mg·mL-1 lysozyme
solution in phosphate buffer solution (pH 7.00) was added dropwise to the stirred solution of
purified MUA-ZnO NPs at ambient conditions. The final concentration of lysozyme in the
solution was 60 µM. The particles were purified as stated before and layered with PSS (1000
kDa). A solution of 10 mg·mL-1 PSS in deionized water was added dropwise to a stirred solution
of Lys-MUA-ZnO NPs at room temperature to end with a final concentration of 2 mg·mL-1 of
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PSS. Then, after washing, a solution 10 mg·mL-1 PEI (60 kDa) in deionized water was added
dropwise to a stirred solution of PSS-Lys-MUA-ZnO NPs at room temperature to end with a
final concentration of 2 mg·mL-1 of PEI. The PSS-PEI-MUA-ZnO NPs could be layered
according to the above procedure, just with a different order of layers. Each sample would be
sequentially layered as stated above to form PEI-PSS-Lys-PSS-PEI-MUA-ZnO NPs and PEIPSS-Lys-MUA-ZnO NPs.
Characterization would take place after each layering procedure using DLS, ELS, FTIR
spectroscopy, and UV-Vis spectrophotometry for these nanoparticle conjugates. Each sample
would be washed and purified, resuspended in 1 mM NaCl, and then analyzed with each
instrument. After all the layering was completed, the starting material, ZnO-MUA nanoparticles,
and the final layered nanoparticle conjugates were observed and imaged using the SEM. These

Figure 15. Methods for synthesizing zinc oxide nanoparticle conjugates without the use of a
stabilizing agent (Method 1) and with the use of the stabilizing agent MUA (Method 2).
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images were then compared to examine the difference in the particles before and after the
layering process. Enzymatic activity assays were completed following all other characterization
techniques.

Section 2.4 Synthesis of PEI-PSS-Lys-ZnO NPs
Zinc oxide nanoparticles were synthesized in a different fashion for the addition of
lysozyme directly to the nanoparticles as shown in Figure 14 (Method 1).27 A 500 mL, threeneck round bottom flask was placed in a heating mantel. Each spout was filled as follows: a
thermometer for temperature control was placed in the left-neck with a rubber septum; a
condenser with a KIM wipe loosely stoppering the top was placed in the middle-neck to control
evaporative effects; a 150 mL separatory funnel was placed in the right-neck with a rubber
septum. Then, 50 mL of 1.00 M NaOH was put inside the flask with a stir bar. The flask was
heated to a temperature of 90oC with stirring at 400 rpm. Next, 50 mL of 0.50 M zinc chloride
was placed in the separatory funnel for slow addition to the flask. Once the NaOH reached its
desired temperature, the zinc chloride solution was added dropwise very slowly to the solution. It
took approximately 45 minutes for all of the zinc chloride to be added. The solution was allowed
to sit for an additional two hours to finish reacting. The resulting precipitate was filtered using a
vacuum pump and a filter flask. It was washed with several portions of deionized water and then
removed from the funnel with the filter paper. The resulting solid was placed in the oven at 60oC
for one day to dry it out.
From there, the layering could proceed. To add the first layer, 5 mg·mL-1 of lysozyme
was placed in a centrifuge tube with 100 µL of phosphate buffer (pH 7.00) and 900 µL of
deionized water. The absorbance was measured at 280 nm and recorded. Then, 10 mg·mL-1 of
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the synthesized ZnO NPs were added to the centrifuge tube and incubated from one day then
centrifuged for ten minutes at 13,000 rpm. The absorbance of the solution was taken again to
determine if the lysozyme binded to the ZnO NPs. The resulting Lys-ZnO NPs were purified by
centrifugation at 5000 rpm, washed with deionized water, and resuspended in 1 mM NaCl as
described above. The coating of Lys-ZnO NPs with PSS and PEI was completed using the same
techniques as for the MUA-ZnO NPs for a final product of PEI-PSS-Lys-ZnO NPs.
Just like the nanoparticle conjugates of ZnO-MUA, these conjugates were characterized
using DLS, ELS, FTIR spectroscopy, and UV-Vis spectrophotometry after each deposition took
place. Each sample was washed, purified, resuspended in 1 mM NaCl, and then analyzed as
before. After all the layering was completed, the starting material of ZnO nanoparticles and the
final nanoparticle conjugates were observed and imaged using the SEM. These images were then
compared to see the difference between the starting material and final product.

Section 2.5 Lysozyme Activity Assay
The residual activity of the lysozyme within the layered nanoparticle conjugate was
tested using a lysozyme activity assay with the UV-Vis spectrophotometer.16 Bacteria
Micrococcus lysodeikticus was used as a substrate for the enzymatic action of lysozyme. The
concentration of encapsulated lysozyme was determined spectrophotometrically using an
extinction coefficient of 2.63 mL·mg-1·cm-1 when measuring the absorbance at 280 nm. This
value is most likely the same for encapsulated lysozyme due to it having the same properties in
and out of encapsulation. Micrococcus lysodeikticus solution was prepared by dissolving 50 mg
of bacteria in 100 mL of 50 mM buffer phosphate (pH 6.25). The ZnO NPs samples and free
lysozyme were dissolved in 50 mM buffer phosphate (pH 6.25) each. 600 µL of the sample was
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added to 3 mL of bacteria solution at room temperature and mixed. The decrease in the
absorbance was monitored continuously at 600 nm for 30 minutes at room temperature. The
enzymatic activities were determined from the slope of the fitted line when representing the
absorbance decay plots and using the following equation:

𝑈𝑛𝑖𝑡𝑠
𝑚𝐿𝑒𝑛𝑧𝑦𝑚𝑒 𝑠𝑎𝑚𝑝𝑙𝑒

=

(∆𝐴𝑏𝑠600 / min 𝑡𝑒𝑠𝑡 − ∆𝐴𝑏𝑠600 / min 𝑏𝑙𝑎𝑛𝑘)
0.001 × 0.6

where 0.001 is the change in the absorbance per minute for lysozyme, and 0.6 is the added
volume of sample to the bacteria solution during the tests measured in mL16. The blank used for
the assays was 50 mM phosphate buffer. The residual activity (%) was calculated as the ratio of
the activity at time t to the initial activity multiplied by 100.
From there, the residual activities calculated from each sample were graphed vs. time and
compared to the free lysozyme sample. These activities can also be compared to other
nanoparticle conjugates to determine how effective the order of layering and residual activities
were. In addition, it can be hypothesized whether or not these particles would work for the
transport into cells when looking at these results.

Section 2.6 Synthesis of PEI-RNA-PEI-MUA-ZnO NPs
For the encapsulation of RNA instead of lysozyme, the same layering procedure was
completed but using a sample of RNA instead and a different order of layers.12 For this
experiment, the ordering of layers was ZnO-MUA-PEI-RNA-PEI for the final nanoparticle
conjugate as shown in Figure 16. The ZnO-MUA nanoparticles were synthesized slightly
different from the procedure described before. Instead, 50 mL of 1.0 M NaOH was heated in a
flask to 90oC. While heating, 0.04 g of MUA was added to the flask and dissolved. After this
solution reached its designated temperature, 50 mL of 0.5M ZnCl2 was added using a separatory
33

Figure 16. Encapsulation of RNA method for synthesizing zinc oxide nanoparticle conjugates
with the stabilizing agent MUA.
funnel. The zinc chloride was added dropwise over a period of about an hour. Once the addition
was over, the solution was removed from heat, washed, and resuspened in 1mM NaCl for further
layering.
The first layer of PEI (25 kDa) was added as before starting with a 10mg/mL stock
solution and adding it dropwise to the nanoparticles for a final concentration of 1mg/mL. The
sample was washed and purified as before with DI water and centrifugation, and resuspended in
1mM NaCl. The RNA was added next according to the Layer-by-Layer technique discussed
earlier.12 A stock solution of 1mg/mL RNA was made with DI water and stored in the fridge
when not in use. This sample was added dropwise to the stirred solution of ZnO-MUA-PEI
nanoparticles for a final concentration of 0.2 mg/mL. It was left to stir for 30 minutes at room
temperature to bind and stabilize. The sample was then washed and resuspended in 1mM NaCl
for the last deposition step. The last layer of PEI was added exactly as before with a final
concentration of 1mg/mL. The resulting particles were stored without washing, with excess PEI
in solution, for multiple weeks for testing. When ready to analyze, the particles were washed and
resuspended in 1mM NaCl.
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Again, the nanoparticle conjugates were characterized using DLS, ELS, FTIR
spectroscopy, and UV-Vis spectrophotometry after each deposition process. Each sample was
washed, purified, resuspended in 1 mM NaCl, and then analyzed. After the entire layering
process was finished, the starting material of ZnO-MUA nanoparticles and the final layered
nanoparticle conjugates were observed and imaged using the SEM. The starting material and
final product could then be compared for differences as well as compare these samples to the
ones with encapsulated lysozyme.

Section 2.7 RNA Integrity Analysis
The RNA integrity analysis was completed by addition of ethidium bromide and
measuring the resulting fluorescence of the solution. To begin the ethidium bromide assay, a
sample of free RNA was used to determine the difference in absorbance between an intact RNA
strand and a degraded RNA strand.44 For this test, 970 µL of 230 µg/mL RNA in 0.1 M PBS
buffer at pH 7.4 were added to two separate test tubes.45 Then, 29 µL of 500 µg/mL ethidium
bromide was added for a final concentration of 36.9 µM in PBS buffer at pH 7.4.46 These two
samples were covered in foil to protect the ethidium bromide from reacting with the light, which
would reduce its affinity to bind to RNA. To degrade one of the RNA samples, two methods
were attempted. First, a couple drops of 0.1 M HCl was added to the test tube and mixed. The
second method involved heating the original sample to 120oC in a water bath for approximately
10 minutes. Following each degradation process, a color change was observed from pink to a
faint orange. The fluorescence was then measured for the two samples to assure that the
degraded sample would have a lower fluorescence. It was measured with an excitation
wavelength of 510 nm with a length of 520 nm to 700 nm for both test tubes.44

35

Following that procedure, the nanoparticle conjugate sample was tested the same way. To
begin, 480 µL of 0.1 M PBS buffer at pH 7.4, 480 µL of purified ZnO-MUA-PEI-RNA-PEI
nanoparticles, and 15 µL of 500 µg/mL ethidium bromide were pipetted into two test tubes.45
Both tubes were mixed well and covered with foil. These samples had the same pink color as the
nondegraded standard RNA samples. Then, a couple drops of 0.1 M HCl were added to one of
the test tubes to attempt to degrade the RNA in the sample. In addition, the process was repeated
with the other degradation method of heating the sample to 120oC for 10 minutes in a water bath.
Both methods showed the samples quickly turn from pink to orange just like the standard
samples. From there, all the samples had their fluorescence tested with an excitation wavelength
of 510 nm and measured from 520 nm to 700 nm.44 The fluorescence of the nondegraded sample
and the degraded one could then be compared to see if there was a difference.
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CHAPTER 3. RESULTS AND DISCUSSION

After synthesizing each nanoparticle conjugate encapsulating one of the two biological
materials, characterization was completed to ensure that each layer was successfully bound to the
layer before through electrostatic interactions. Furthermore, the biological material was checked
for its activity to assure that it was still useful for cell transport once encapsulated. This section
describes the results and interpretations obtained from each instrumental analysis before, during,
and after the deposition process for each nanoparticle conjugate sample. Furthermore, these
results will be discussed and compared to determine the effectiveness of these experiments.
X-ray diffraction was used to confirm the crystal structure of the synthesized zinc oxide
nanoparticles used for all of the following layering techniques. Figure 17 shows the XRD pattern
of the sample. When compared to literature patterns of XRD for different crystal structures, this

Figure 17. XRD pattern of synthesized zinc oxide nanoparticles.
pattern shows the wurtzite structure as hypothesized.56 The specific peaks confirming this are the
three between 30 and 40 degrees, one at 47 degrees, and one at 56 degrees. In addition, due to it
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being a bulk sample with particles at about 200 nm in diameter, there are some extra peaks
visible which can be attributed to this.

Section 3.1 Encapsulation of Lysozyme
The following sections discuss the results for the encapsulation of lysozyme with the
same techniques and ordering of layers as the past research with gold nanoparticles. The two
methods were compared along the way for similarities, differences, and which method worked
better.
Section 3.1.1 UV-Vis Spectrophotometry. When layering the zinc oxide nanoparticles,
an absorbance spectrum was obtained after each layer to show the basic composition of the
solution using the UV-Vis spectrophotometer. All three orders of layering were analyzed after
each deposition from the original nanoparticle sample to the final nanoparticle conjugate with the
encapsulated biological material. The absorbance was measured from 200 to 800 nm with 1 mM
NaCl being used as the blank. Some of the compounds used in this experiment have known
absorbance peaks that can be used to identify and confirm their presence in the solution
containing the nanoparticle conjugates. Specifically, zinc oxide is known to absorb light at 360
nm providing a strong peak at that wavelength depending on the concentration of it.31 This is the
main peak observed in each absorbance spectrum due to zinc oxide being the core of the
conjugate. Further analysis involves the known absorbance of lysozyme at 280 nm due to the
amino acids present in its structure, and the absorbance peaks of PSS observed at 260 nm and
228 nm.12,16 From here, the absorbance of each sample was measured and observed.
Figure 18 shows the absorption spectra of the synthesized ZnO-MUA nanoparticles after
each layer was added for a final product of ZnO-MUA-Lys-PSS-PEI. The major peak being
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looked at is the one at 360 nm for the starting material of zinc oxide that did not have MUA as a
stabilizing agent in its synthesis procedure. This peak confirms the presence of zinc oxide in the
solution. To add the first layer, MUA, to the nanoparticles, zinc oxide was synthesized with
MUA in the solution. Due to this, the peak at 360 nm was greatly decreased in size due to the
outer most layer of MUA being at such a high concentration. Continuing in the deposition
process, the characteristic absorbance peak of lysozyme was observed at 280 nm. The
characteristic absorbance peak of PSS is also well seen when it is the outside-most layer at 260
nm. Although the zinc oxide peak at 360 nm should be more visible in each spectrum, the overall
data does confirm the presence of each deposition layer. The concentration of MUA was
adjusted for further synthesis processes with the other nanoparticle conjugates so that the zinc

Figure 18. Absorbance Spectra for ZnO-MUA-Lys-PSS-PEI layered nanoparticle samples
after each deposition.
oxide peak was visible through each deposition. Overall, for this sample, each deposition was
successful, and these results with the model protein of lysozyme were used to optimize the later
synthesis and encapsulation of RNA in the nanoparticle conjugates.
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The absorbance spectra for the ZnO-Lys-PSS-PEI samples were also obtained and are
shown in Figure 19. After each deposition, the absorbance was measured from 200 to 800 nm
with the blank being 1 mM NaCl as with the other samples. The characteristic zinc oxide peak
was seen in all spectra at 360 nm which was expected due to the MUA not being present. This
result is the goal for the RNA encapsulated nanoparticle conjugates completed following this

Figure 19. Absorbance Spectra for ZnO-Lys-PSS-PEI layered nanoparticle samples after each
deposition.

experiment. Specifically, the concentrations of ZnCl2 and NaOH to synthesize the zinc oxide
nanoparticles described in the experimental sections were used for the synthesis of ZnO-MUA
nanoparticles for the RNA encapsulation process. From there, the lysozyme peak was observed
at 280 nm as expected in the next spectrum. The characteristic PSS peak is also seen well at
about 230 nm. This absorbance is different than the previous sample but it is due to the PSS
having an overall different concentration. PSS absorbs at both 260 nm and 228 nm, but whether
both peaks are observed depends on how dilute the solution is. In brief, these spectra do show the
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presents of the zinc oxide and lysozyme as was predicted. It can be concluded with this
preliminary data that each layer did bind to the nanoparticle conjugate to form the overall vessel
with lysozyme encapsulated inside. These results compared to previous with MUA used as a
stabilizing agent were looked at, and the methods were actually combined to synthesize and
characterize the last nanoparticle conjugate with RNA.
Section 3.1.2 Scanning Electron Microscopy. Due to the very small size of the
nanoparticle conjugates, hence the “nano” in the name, microscopy was used to observe each
sample. Specifically, a scanning electron microscope was used to image and observe the size and
morphology of the zinc oxide nanoparticles before and after the deposition process. With these
images, the general size and shape of the particles was observed. To begin, the ZnO-Lys-PSSPEI nanoparticle conjugates were evaluated. Figure 20 (A) shows the synthesized zinc oxide
nanoparticles before any depositions took place. They have a spherical shape although it was not
uniform across the whole film. The size of each particle was estimated at 150 nm using the scale

A

B

Figure 20. SEM images taken for the ZnO-Lys-PSS-PEI NP samples (A) before and (B) after
deposition with the scale bar in the right corner of each to estimate the size of the particles.
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bar in the lower right corner of the image. Figure 20 (B) has the ZnO NPs after the deposition
process, specifically for the ZnO-Lys-PSS-PEI ordering. These particles were observed to be 250
nm, although the size and shape varied greatly between each particle as seen in the image.
Furthermore, these particles were much more aggregated after the layering process took place.
Comparing both images, the particles did increase in size after the layering process as expected,
and the shape remained mostly spherical after all the layers were added.
The second method for synthesizing the nanoparticle conjugates to encapsulate lysozyme
used MUA as a stabilizing agent in the synthesis of the zinc oxide nanoparticles. The deposition
process was analyzed just as before with the SEM imaging the particles before and after the
process was completed. Figure 21 (A) shows the particles before deposition took place which is
for the ZnO-MUA NP sample. These particles were shown at about 200 nm in diameter and were
mostly spherical, although some rough edges were observed accounting for the crystal structure
of wurtzite.22 Figure 21 (B) shows the nanoparticle conjugates after deposition with a final
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Figure 21. SEM images taken for the ZnO-MUA-Lys-PSS-PEI NP samples (A) before and
(B) after deposition with the scale bar in the right corner of each to estimate the size of the
particles.
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ordering of layers as follows: ZnO-MUA-Lys-PSS-PEI. These particles ranged from about 400
nm to 500 nm and became more aggregated. As seen in the image, the particles started to acquire
needle-like structures on the outside of the spheres during the layering process. Overall, these
particles increased in size as expected with layers being added to them.
To sum up, this section shows how the nanoparticle conjugates were hypothesized and
confirmed to increase in size after the deposition process was completed. Adding layers to the
original particles should increase the size after each layer was added, so these results are
encouraging. Further sizing measurements with the DLS were taken though to confirm this
hypothesis.
Section 3.1.3 Dynamic Light Scattering. When beginning the synthesis process for the
zinc oxide nanoparticles, many well-known methods have been used to synthesize them by
themselves. However, adding MUA into the solution to bind the ligand onto the outside of the
nanoparticle while synthesizing the nanoparticle in question creates a new protocol to optimize.
This new protocol would involve synthesizing ZnO-MUA nanoparticles all at once. The
parameters of the protocol from synthesizing the particles with and without MUA in the solution
were all the same to begin with except for the time allowed for the reaction to occur. With MUA
present, the reaction time was varied from 1 hour to 24 hours, with the diameter of the particles
being measured immediately after synthesis and washing. Figure 22 shows the diameter of the
zinc oxide nanoparticles versus the reaction time to compare the differences observed. As shown
by the graph, as reaction time increases so does the diameter of the nanoparticles. At a reaction
time of 1 hour, the nanoparticles averaged 170 nm, while at 24 hours had a diameter of about 290
nm. Any size of these nanoparticles would be useful in this research, but it is helpful to be able to
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Figure 22. Nanoparticle diameter versus reaction time for the synthesis of zinc oxide
nanoparticles coated with MUA.
predict the size of the nanoparticle conjugates based on the initial reaction time. The goal would
also be to use the smallest possible nanoparticle size for further research.
Although using the SEM to estimate the size of the nanoparticle conjugates was useful, it
was not enough to settle with just these results. To determine the exact diameter of the
nanoparticles throughout the synthesis and layering process, Dynamic Light Scattering
spectroscopy (DLS) was used after each step. After each deposition, the diameter and
polydispersity of the nanoparticle samples were measured. Multiple trials were completed for
each layering order starting with the synthesized zinc oxide nanoparticles and ending with a layer
of PEI. The trials involved making a completely new sample of nanoparticle conjugates for each
measurement process. These diameters could then be compared to the estimated values observed
from the SEM. With both measurements, the size of the nanoparticles can be confirmed.
Furthermore, the polydispersity shows how uniform the particle size is across the sample.
Ideally, this value should be low.
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For the first sample of ZnO-MUA-Lys-PSS-PEI, the size and polydispersity is shown in
Figure 23 after each layer averaging four trials. The polydispersity is also seen on the right axis
of this graph. The particles started at 159 nm after the synthesis of the original zinc oxide
nanoparticle with MUA in the solution. Moving to the next layer with lysozyme, the size greatly
increased to 368 nm which was higher than expected. With the addition of PSS, the size actually

Figure 23. Particle diameter (left axis) and polydispersity (right axis) of ZnO-MUA-Lys-PSSPEI conjugates measured with the DLS with mean and standard deviation labelled.
decreased to 211 nm which is about where the particle size was expected to be at this point. The
decrease in size for this deposition is hypothesized to be due to the electrostatic interactions.
Going from the positive lysozyme step to a negative PSS layer, if the concentrations of each
were high enough, the attraction would have been very strong between the two. This could have
pulled the final layer even tighter towards the core of the conjugate to cause a decrease in the
diameter. Furthermore, it also could have been Ostwald Ripening or nanoparticle coarsening.51,53
The final layer of PEI increased the size of the conjugate to an ending diameter of 359 nm. The
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polydispersity varied from about 0.2 to 0.4 throughout the layering process showing that the
particle size was well dispersed throughout the solution. In brief, these results do match the
estimated values from the SEM being within 50 nm each.
For the next ordering, the zinc oxide was bound directly to the lysozyme layer without any
stabilizing agent for a final ordering of ZnO-Lys-PSS-PEI. The diameter and polydispersity were
also measured for this sample after each deposition and is shown in Figure 24 for an average of
four trials. The synthesis of these particles started out as just zinc oxide with no other layers
added unlike the previous sample. The starting diameter of the ZnO was 124 nm. With each
deposition, these particles increased in size as expected. The lysozyme layer increased the
diameter to 210 nm, PSS layer to 297 nm, and the PEI layer to a final size of 323 nm. The
polydispersity decreased with each layer, meaning the particles became more uniform in their
size throughout the deposition process ending at about 0.16. Again, these results with the DLS

Figure 24. Particle diameter (left axis) and polydispersity (right axis) of ZnO-Lys-PSS-PEI
conjugates measured with the DLS with mean and standard deviation labelled.
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were compared to the ones from the SEM. The SEM showed that the particles were slightly
smaller in the end than the DLS measured, however were still somewhat close. This difference in
measurements could have been due to aggregation between the particles causing a larger reading
from the DLS.
With these results from the SEM and the DLS, the size of the nanoparticle conjugates can
be confirmed to be nano-sized and verified as the values seen above. The diameter steadily
increased with each deposition as hypothesized ending at a size ranging from 300 to 400 nm.
Any non-consistent values of increasing diameter can be attributed to Ostwald Ripening or
coarsening causing the nanoparticles to shrink and grow in an unpredictable manor.51,53 Although
much larger than the gold nanoparticle conjugates this research is based off of, these nanoparticle
conjugates can still be used for drug delivery and could be reduced in size by adjusting some of
the parameters in future experiments.
Section 3.1.4 Electrophoretic Mobility Light Scattering. Along with measuring the
diameter of the particles, the zeta potential was also measured after each deposition to assure
each layer did bind as expected. The layers interact through electrostatic interactions from their
oppositely charged surfaces. Therefore, when looking at the zeta potential after each deposition,
if the next layer binds, the surface charge measured should switch to the opposite charge, and
therefore be alternating with each measurement. Each nanoparticle conjugate sample was
measured to determine the surface charge after each deposition. The zeta potential values for the
layers without the nanoparticle conjugates are shown in Table 1 to the what charge is expected
for each layering.16,47,48 The exact value depends on the concentration of the compound as well
as the pH at which the measurement was taken. This is why it will vary from reading to reading,
but this table gives the general idea of the charges that should be observed.
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Table 1. Zeta potential values and standard deviations for MUA, PEI, PSS, Lysozyme, and
RNA individually.

The first sample measured was the ZnO-MUA-Lys-PSS-PEI nanoparticle conjugates.
Figure 25 shows the average of four zeta potential measurements for the sample. The first
measurement for the synthesized zinc oxide particles with MUA in the solution had a zeta
potential of -20 mV. Since MUA has a negative charge at physiological pH, there results were

Figure 25. Zeta potential measurements for the ZnO-MUA-Lys-PSS-PEI layered nanoparticle
samples after each deposition with mean and standard deviation labelled.
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expected. Further layers had the proper charges switching off being positive and negative with
+22 mV for lysozyme, -25 mV for PSS, and ending with +23 mV for the layer of PEI on the
outside. These results show that the deposition process was successfully completed for each layer
and have similar values to the literature values. They do vary however due to the concentrations
of the compounds being different.
The sample with zinc oxide attached directly to lysozyme without any stabilizing agent
also had the zeta potential measured after each deposition. This sample had the order of layering
as ZnO-Lys-PSS-PEI. Figure 26 shows this for the average of four trials after each layer was
added. The zinc oxide nanoparticles without anything bound to them had an average of +4 mV
for the surface charge. The next layer, lysozyme, also has a positive charge which is why this

Figure 26. Zeta potential measurements for the ZnO-Lys-PSS-PEI layered nanoparticle
samples after each deposition with mean and standard deviation labelled.

binding process took much longer than the other ones (i.e. 24 hours vs. 1 hour). After incubation,
the ZnO-Lys sample was measured to have a surface charge of +8 mV. This ideally should have
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been higher due to lysozyme being a very positive enzyme at physiological pH. Continuing the
layering process, PSS was bound for a charge of -40 mV and finally PEI with a charge of +36
mV as expected. Again, this shows that the deposition process for this sample was successful for
the encapsulation of lysozyme in the nanoparticle conjugate since each deposition had the charge
switching between positive and negative. The lysozyme binding directly to the zinc oxide
nanoparticles worked, but not to the extent that was hoped. The zeta potential measured for ZnOLys was lower than expected, which is most likely due to the binding method and that it’s a
positive to positive interaction. Therefore, although this method did work, the RNA nanoparticle
conjugate will use the stabilizing agent of MUA in the deposition process to assure the binding
of each layer is through strong electrostatic interactions.
These zeta potential values for each nanoparticle conjugate as well as the known
electrostatic interactions between each layer were another method for confirming the successful
deposition of each layer and the overall encapsulation of lysozyme. With the results given so far,
the deposition process has been shown to work using each characterization technique.
Section 3.1.5 Fourier-Transform Infrared Spectroscopy. In addition to the other
characterization techniques completed, IR spectroscopy was also used to confirm the presence of
MUA and the encapsulated species within the nanoparticle conjugate. When looking at the
known spectra for these materials, MUA should have peaks at about 2900 cm-1, 2600cm-1, and
1680 cm-1. These represent the saturated alkyls, the sulfur, and the carboxylic acid respectively
in the MUA chain.49 Lastly, lysozyme can be characterized by its two known amide peaks
around 1650 cm-1 for Amide I and 1540 cm-1 for Amide II.16 With these known values, the IR
spectra for the nanoparticle conjugate samples were analyzed. When analyzing these samples, it
was found that the PEI and PSS layers did not have any effect on the spectra obtained, so
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therefore were not included in this data. The purpose of this section was to see that lysozyme was
present in the sample by observing the amide peaks.
The first nanoparticle conjugate looked at was with lysozyme bound directly to the zinc
oxide nanoparticle. Figure 27 shows this sample before and after the deposition of the lysozyme
layer to compare and confirm the presence of the enzyme. The spectra for the original zinc oxide
sample and for the lysozyme layered sample, ZnO-Lys, were graphed together to be able to
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Figure 27. FTIR Spectra for ZnO-Lys-PSS-PEI samples before and after the deposition of
lysozyme with the amide peaks labelled.
compare peaks easily. The main peaks to notice are the two amide peaks labelled at 1650 and
1530 cm-1 for ZnO-Lys in correlation with the literature peaks.16 The other peaks, some labelled,
were not important to this analysis technique. The two amide peaks correlate to the amides in the
amino acids of lysozymes sequence. The presence of these peaks show that lysozyme was in fact
bound to the zinc oxide in this sample. Looking at the ZnO sample, there are no amide peaks
seen which was expected due to no lysozyme being present in that sample. Moreover, these
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spectra show the presence of lysozyme in this nanoparticle conjugate sample. These results along
with others confirm the deposition of lysozyme.
The other sample characterized with IR spectroscopy was ZnO-MUA-Lys-PSS-PEI.
Specifically, the spectra measured were for the starting material of ZnO-MUA and the first
deposition of lysozyme and are shown in Figure 28. The first was for the original nanoparticle
conjugates, ZnO-MUA. Looking at the spectra, the blue spectrum has peaks corresponding to the

Transmittance

Wavenumber (cm-1)

Figure 28. FTIR Spectra for ZnO-MUA-Lys-PSS-PEI samples before and after the deposition
of RNA with the amide peaks labelled.
functional groups of MUA in accordance with the literature which are labelled.49 To see that the
-SH peak was actually present, a zoomed in image is in the bottom right corner of the figure.
Further analysis with the ZnO-MUA-Lys sample showed the amide peaks where they were
expected to be seen at 1650 and 1540 cm-1. These peaks are less intense than literature spectra
show, but was expected due to the high concentration of MUA in this sample. Overall, MUA and
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lysozyme were shown to bind to the nanoparticle conjugate as hoped for. Again, these results
show that lysozyme was successfully bound and encapsulated into the vessel.
These spectra were in accordance with the UV-Vis spectra shown previous sections
showing the presence of lysozyme in each sample. Peaks were visible in each type of spectrum
accounting for the species on the outside of the conjugate. With all the characterization analyses
completed thus far, it can be concluded that the deposition process for each of these nanoparticle
conjugates were completed successfully for the encapsulation of lysozyme. Next, the integrity of
each material must be tested to assure that it will still be active and, therefore, useful once
transported through a cell membrane.
Section 3.1.6 Activity of Lysozyme. The last experiment to characterize the synthesized
zinc oxide nanoparticles encapsulating lysozyme was a lysozyme activity assay using the UVVis spectrophotometer. This was done to verify the activity of lysozyme within the layered
particles. The enzymatic activities for free lysozyme and for the encapsulated lysozyme within
the zinc oxide nanoparticles were monitored for 30 minutes within the UV-Vis
spectrophotometer. The bacteria sample was added to the bioconjugate sample to see how the
surface interaction between them evolved. Figure 29 shows the enzymatic activities of each
sample over time. After 5 minutes, the activity of free lysozyme greatly decreased and reached
zero after 15 minutes. This shows that after this amount of time, the native lysozyme had fully
digested the bacteria in the assay. Then, when looking at both encapsulated lysozyme samples,
the activity had a much different behavior due to the particles being layered causing the
lysozyme not to be released into the bacteria immediately. Overall, the enzymatic activity
increased in the first 10 minutes for each sample due to the polymeric layers on the outside of the
conjugate. After 10 minutes, the ZnO-MUA-Lys-PSS-PEI conjugates began to decrease in
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Figure 29. Lysozyme activity assay for a free lysozyme sample and the two layered samples
when added to a solution of bacteria measured in EU/mLenzyme sample. (error bars on all data
points, some not visible due to precision)
enzymatic activity reaching nearly zero at 25 minutes. On the other hand, the ZnO-Lys-PSS-PEI
conjugates continued to have an increase in the enzymatic activity after 10 minutes reaching a
plateau by 25 minutes. Zinc oxide has a high affinity for enzymes which may have prolonged the
activity of the lysozyme once in the bacteria.
These results for the samples encapsulating lysozyme show that the nanoparticle conjugate
could be transported into a cell before the lysozyme would be released. The vessel would
penetrate the cell membrane before diffusion of the enzyme would take place due to the outside
layers of PSS and PEI needing to be removed first. Therefore, these results show that lysozyme
was still active inside the nanoparticle conjugates after a certain time. Furthermore, these results
match the gold nanoparticle conjugate results very well with the activity increasing for both
layered samples in that case, too. With these results in accordance with each other, the lysozyme
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encapsulation process can be concluded to work for its transport into cells via a nanoparticle
delivery system.

Section 3.2 Encapsulation of RNA
After completed the first goal of synthesizing a delivery system using zinc oxide
nanoparticles, the model protein encapsulated was replaced with a more useful drug. The results
here show how RNA was successfully encapsulated within the nanoparticle conjugate for
transport into cells. The layering was ordered as follows: ZnO-MUA-PEI-RNA-PEI.
Section 3.2.1 UV-Vis Spectrophotometry. The last nanoparticle conjugates made in this
experiment were synthesized to encapsulate RNA instead of lysozyme. The ordering of layers
changed due to the PSS being unnecessary, so it was not seen in the spectra at all. For the ZnOMUA-PEI-RNA-PEI sample, the absorbance spectra were obtained from 200 to 800 nm with 1
mM NaCl being used for the blank as before. Figure 30 shows the absorbance spectrum after

Figure 30. Absorbance Spectra for ZnO-MUA-PEI-RNA-PEI layered nanoparticle samples
after each deposition.
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each deposition for this process. The zinc oxide concentration was increased for these particles,
while the MUA concentration was decreased (see experimental section for exact concentrations),
making the characteristic zinc oxide peak at 360 nm present in each spectrum throughout the
layering process. Specifically, the zinc oxide peak was seen as expected in each spectrum at 360
nm, although the intensity was much lower in the final product due to the high concentration of
PEI on the outside. When RNA was the outer-most layer, its characteristic peak was seen very
well at 260 nm showing the successful deposition of RNA to the conjugate. However, once PEI
was layered on top of it, the peak intensity decreased immensely, which was similar to the zinc
oxide peak, but can still be observed at 260 nm. Overall, the presence of RNA and zinc oxide
were confirmed with these spectra meaning that these preliminary results show that this method
is effective.
Section 3.2.2 Scanning Electron Microscopy. As before, the SEM was used to analyze
the nanoparticles encapsulating RNA before and after deposition. For the ZnO-MUA-PEI-RNAPEI NP sample, these nanoparticles were synthesized with slightly different parameters than the
ones discussed earlier (See experimental section for specific conditions). The deposition process
was looked at before anything was added to the particles and after all the layering was
completed. Figure 31 (A) shows the nanoparticle conjugates of ZnO-MUA before any layering
occurred. With the new synthesis process, these particles were observed to have a needle shape
to begin with their length averaging around 250 nm with a much smaller diameter meaning they
were still nano-sized as expected. Figure 31 (B) then shows the nanoparticle conjugates after the
entire deposition process was completed. These particles have an ordering of layers as ZnOMUA-PEI-RNA-PEI. Again, these nanoparticle conjugates have a needle-like shape and were
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Figure 31. SEM images taken for the ZnO-MUA-PEI-RNA-PEI NP samples (A) before and
(B) after deposition with the scale bar in the right corner of each to estimate the size of the
particles.
more aggregated after the deposition process. However, their size did increase to have a thicker
diameter and longer length of about 500 nm as expected. These results were not exactly what
was expected with the shape of the particles, although the parameters could easily be changed in
the original synthesis process to make the nanoparticles more spherical than needle-like. To do
this, the temperature the particles were synthesized at would need to be increased. The MUA in
the synthesis process was hypothesized to change the exact parameters needed for spheres to
form.
Section 3.2.3 Dynamic Light Scattering. The nanoparticle conjugates encapsulating
RNA with a final ordering of ZnO-MUA-PEI-RNA-PEI were further analyzed with the DLS for
diameter and polydispersity measurements. These were measured after each deposition and are
shown in Figure 32 for an average of four trials. The starting material of ZnO-MUA was
measured at 250 nm. As each following layer was added, the nanoparticle conjugate increased in
size as expected with the PEI layer being 290 nm, RNA at 397 nm, and the final product at 488
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Figure 32. Particle diameter (left axis) and polydispersity (right axis) of ZnO-MUA-PEIRNA-PEI conjugates measured with the DLS with mean and standard deviation labelled.

nm with the outside layer of PEI. Although these particles are larger than the other samples
synthesized with lysozyme instead of RNA, the deposition process still worked well and showed
a preliminary conclusion that RNA was encapsulated successfully. These results also matched
well with the SEM measurements to within 20 nm.
Section 3.2.4 Zeta Potential. As previously discussed, the RNA nanoparticle conjugate
sample has a layering of ZnO-MUA-PEI-RNA-PEI to have electrostatic interactions between
each layer. These samples had the zeta potential measured after each layer to assure the
encapsulation of RNA. Figure 33 shows the charge after each layer for this sample averaging
four trials. The beginning sample of ZnO-MUA started with a charge of -25 mV. From there, it
increased to +31 mV with PEI, decreased to -17 mV with RNA, and back to +26 mV with the
last layer of PEI. The RNA had a negative zeta potential value as expected showing the
successful deposition of that layer to the nanoparticle conjugate. Overall, this sample had each
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Figure 33. Zeta potential measurements for the ZnO-MUA-PEI-RNA-PEI layered
nanoparticle samples after each deposition with mean and standard deviation labelled.

layer bound as expected to the conjugate with high zeta potential values representing high
concentrations.
Section 3.2.5 Fourier-Transform Infrared Spectroscopy. Looking at RNA, its FTIR
spectrum depends specifically on the sequence of the RNA used. Generally, according to
literature, it should have peaks in the range of 1700 to 1400 cm-1 showing the G, A, C, and U
bases in the sequence. In addition, it will have a peak around 1220 cm-1 for the PO2- ribose
asymmetric stretch.50 The nanoparticle conjugate with RNA encapsulated inside had two FTIR
spectra obtained for it. The first was for the original nanoparticle conjugates, ZnO-MUA.
Looking at the spectra shown in Figure 34, the blue spectrum shows the functional groups of
MUA in accordance with the literature with the peaks labelled.49 To see the -SH peak was
present, a zoomed in image is in the bottom right corner. The second spectrum shown for this
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particular sample was after the deposition of RNA with the ordering of ZnO-MUA-PEI-RNA.
Although the literature peaks for RNA are very general, specific ones can be seen from 1650 to
1450 cm-1 representing the G, A, C, and U bases present in the sequence.50 Furthermore, the
PO2- bonded to the ribose is seen at 1222 cm-1 as expected. Overall, this shows the successful
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Figure 34. FTIR Spectra for ZnO-MUA-PEI-RNA-PEI samples before and after the
deposition of RNA with the important peaks labelled for MUA.

deposition of MUA in the original sample and of RNA in the final sample. Due to RNA not
having a designated literature IR spectrum, this is not the best way to confirm the presence of
nucleic acids in the nanoparticle samples.
Section 3.2.6 Integrity of RNA. The integrity of the encapsulated RNA was determined
using fluorescence spectroscopy with an ethidium bromide assay. To assure that this process
would work efficiently and to have a standard to compare the experimental sample to, free RNA
was bound to ethidium bromide, degraded, and analyzed as a reference. The RNA degradation
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was completed using two different methods as stated in the experimental section. The first one to
be looked at was the degradation with acid. Figure 35 shows these results for three samples with
various conditions. Ethidium bromide by itself was measured to assure it had very little to no
fluorescence without intercalating into RNA. In addition, RNA was tested by itself and had the
least fluorescence of all the samples. Next, RNA and ethidium bromide were added together
which caused the ethidium bromide to act as a fluorescent tag on the RNA. The fluorescence
then greatly increased as seen on the graph. However, with degradation of the RNA using an

Figure 35. Standard RNA integrity assay using ethidium bromide and fluorescence
spectroscopy for three samples: EB- ethidium bromide, RNA bound to ethidium bromide, and
RNA bound to ethidium bromide with HCl added to degrade the sample.

acid, in this case hydrochloric acid, the fluorescence of the sample decreased to be almost equal
with the ethidium bromide sample by itself. This is due to the RNA being degraded to the point
that it is unusable. For this sample of RNA, it took 40 mmol of 0.1 M HCl to degrade the sample
to that low of an intensity. After the addition of only one drop, the fluorescence began to
decrease and continued with the addition of more acid, as expected. Finally, to assure that the
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bioconjugate would fluoresce due to the RNA and not the PEI, the bioconjugates with layers
ZnO-MUA-PEI were mixed with ethidium bromide. These are shown to be fluorescent but not to
the degree that RNA is with the intercalating agent.
For the next degradation technique, the standard RNA sample was degraded by heating in
a water bath. An RNA sample without any heating was measured for fluorescence along with the
heated sample. Figure 36 shows these results for both samples with ethidium bromide
intercalated into them. The sample with no degradation had a large peak at 600 nm as expected
to show the high fluorescence of ethidium bromide when bound to intact RNA. On the other
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Figure 36. Standard RNA integrity assay using ethidium bromide and fluorescence
spectroscopy for two samples: RNA bound to ethidium bromide, and RNA bound to ethidium
bromide heated at 120oC.
hand, the heated sample had a much lower fluorescence as seen on the graph. The peak is much
shallower than the non-heated sample, meaning that the sample in question was successfully
degraded to a point. However, the fluorescence of this degraded RNA sample is still much higher
than the one degraded by acid seen in Figure 35. Overall though, both degradation techniques
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worked and showed that intact RNA will have a much higher fluorescence than degraded RNA.
This means that this test will work well for determining if the encapsulated RNA sample is
degraded or intact and can therefore be effective in gene regulation once transported into cells.
From there, the integrity of the encapsulated RNA was tested using the same methods as
for the standard RNA. First off, the encapsulated RNA sample was added to ethidium bromide
and measured for fluorescence. Figure 37 shows this trial with a large peak at about 610 nm. At
this point, comparing this sample to the one with only ethidium bromide, it can be assumed that
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Figure 37. RNA integrity assay for the nanoparticle bioconjugates encapsulating RNA using
ethidium bromide and fluorescence spectroscopy: EB- ethidium bromide, bioconjugates
bound to ethidium bromide, and bioconjugates bound to ethidium bromide with various
amounts of HCl added to degrade the sample (shows total amount added).

the RNA is intact. However, to assure that it is, multiple trials were completed with adding
different amounts of acid to this sample to see how the fluorescence was affected. Figure 36
shows the fluorescence spectra for the nanoparticle conjugates encapsulating RNA bound to
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ethidium bromide with acid added ranging from 25 to 100 mmol. As seen in the graph, the
fluorescence slowly decreased as the amount of acid increased showing that the RNA was being
degraded as more acid was added. More acid was needed to degrade the encapsulated RNA than
the free RNA sample due to layers of polyelectrolytes protecting it from the acid in the sample.
Those layers had to be removed by reacting with the acid first before the RNA could be fully
released for degradation.
Next, the second method for degradation was completed for the encapsulated RNA
sample. This degradation method involved heating the encapsulated RNA sample in 120oC water
bath for 10 minutes to start with. Figure 38 shows the original nanoparticle conjugates bound
with ethidium bromide. This sample had a very high fluorescence as expected, shown by the
peak at about 610 nm. The sample was then attempted to be degraded by heating it for 10
minutes. However, this had minimal change to the fluorescence of the sample, so heating was

BC + EB
BC + EB + heat

Intensity

Figure 38. RNA integrity assay for the nanoparticle bioconjugates encapsulating RNA using
ethidium bromide and fluorescence spectroscopy: bioconjugates bound to ethidium bromide,
and bioconjugates bound to ethidium bromide heated at 120oC.
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continued for 30 minutes to assure degradation would take place. After this time in the hot water
bath, the sample had a very low fluorescence as seen in Figure 37. This degradation process took
much longer than expected, however, according to the literature. With the RNA being
encapsulated though, again the polyelectrolyte layers would have to be removed before the RNA
could be degraded within the sample. Therefore, these results do show the proper degradation of
the sample after heating for 30 minutes.
Overall, both ethidium bromide assays for the encapsulated RNA samples show that the
RNA is in fact intact and useable for gene silencing or regulation once transported into cells.
They also show that the layering process worked well in protecting the RNA from its
surroundings for a time which will allow the nanoparticle conjugate to penetrate the cell wall
before releasing the RNA. However, the acid degradation results are more conclusive since no
parameters were changed from one test to the next. The heating method had to be extended for
heating time compared to literature protocols.
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CHAPTER 4. CONCLUSION

Through this research, it was shown that zinc oxide nanoparticles were synthesized with
different modifications to the particles. With near ambient conditions and no activators needed,
these nanoparticle conjugates were easily produced and characterized using zinc chloride and
sodium hydroxide. Three different layering techniques were used, two of which encapsulated
lysozyme, and the other encapsulated RNA. The general basis for encapsulation started with the
zinc oxide nanoparticle core, MUA added for stabilization in some cases, and then
polyelectrolytes and the biological material in question layered after that depending on the
charge of each. The final products were as follows: ZnO-MUA-Lys-PSS-PEI, ZnO-Lys-PSSPEI, and ZnO-MUA-PEI-RNA-PEI.
After each layering step, the diameter, surface charge, FTIR spectrum, and UV-Vis
spectrum were looked at to determine if each deposition was successfully layered. The optical
properties and zeta potential measurements concluded the presence of each layer on to the
conjugate. The diameter measurements showed that the nanoparticles increased in size with each
deposition ending with various diameters for each sample averaging 300 nm. Furthermore, the
images from the SEM allowed observation of the particle size and shape before and after the
deposition process. None of the three nanoparticle samples had a uniform shape across the film
when observed. Ideally, the particles would have been spherical which further research could
possibly fix with increased reaction temperature.
The last characterization techniques completed for the nanoparticle conjugates were the
assays to assure the effectiveness of the biological materials, lysozyme and RNA, once
transported into the cells. These tests had promising results showing that the encapsulated
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material was still active and intact, and that the outside polyelectrolyte layers successfully
protected the material for a time. This will allow for the biological material to be transported into
the cell before the outside layers are removed. Once in the cell and the layers have come off, the
RNA or lysozyme can diffuse into the cell for its biological purpose.
All three nanoparticle conjugates were synthesized with each layer being confirmed,
however, each had particular aspects that worked better due to the particular synthetic process
used. The nanoparticle conjugate encapsulating RNA had the most conclusive results overall. All
layers were seen to bind properly through UV-Vis spectroscopy as well as zeta potential
measurements. Furthermore, the diameter of the particles steadily increased with each layering
by about 30 nm. The only adjustment to be made with these particles are their shape. The SEM
images show long needle-like shapes instead of spheres. Increasing the reaction temperature
would most likely fix this issue according to past research.27 In brief, the ZnO-MUA-PEI-RNAPEI nanoparticle sample worked the best in these synthesis processes.
As for the lysozyme encapsulated samples, these had various unexpected results. These
issues were fixed when redone for the nanoparticle conjugate encapsulating RNA instead of
lysozyme. Specifically, the sample with MUA in it did not have a high enough concentration of
zinc oxide in the sample to begin with. It also did not have a steady increase in diameter as
expected. For the ZnO-Lys-PSS-PEI sample, the zeta potential for lysozyme was not as high as
was hoped, and furthermore, not enough lysozyme was bound into the system.
Overall, the zinc oxide nanoparticle conjugates were synthesized and analyzed
successfully with a few improvements that can be made in the future. Furthermore, the
conjugates showed promising results for the transfection of the proteins into cells. From here,
these nanoparticle conjugates could be tested in the actual transport into cells using past methods
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in the literature. This would show firsthand that these conjugates would work in the transport of
biological material into cells. However, this research has given a general basis to start with and
shown that these nanoparticle conjugates will work as a delivery system as expected.
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